NEW YORK – Cambridge, Massachusetts-based Ymir Genomics said on Wednesday that it has signed a licensing agreement and filed a joint patent application with the Oregon Health & Science University's Knight Cancer Institute that aims to protect and promote newly discovered urinary biomarkers for cirrhosis or hepatocellular carcinoma (HCC).
Ymir and OHSU will share in any value created by the biomarkers and will jointly publish and validate the biomarkers in a large-scale multi-center study.